IPO & New Listings Tracker: Who's Coming to Market, and How New Stocks Trade
The US deal calendar — expected, priced and withdrawn — next to the question calendars never answer: how do recent listings actually trade once they're public? Every return is measured from the first close a buyer could get, never the offer price, and the performance layer is built survivorship-honest: a frozen equal-weight index cross-checked against the investable Renaissance IPO ETF, because our own database only remembers the listings that lived. Cross-check live action on Unusual Volume and the Momentum Scanner.
Latest reading
As of August 21, 2026, recent listings read neutral versus the market: the investable Renaissance IPO ETF's relative strength against SPY sits at the 47th percentile of the post-2013 record, down 0.2% over the past quarter (our own 365-stock survivor cohort is kept as the beneath-the-surface exhibit). On the calendar, 35 deals have priced since August 14, 2026 and 36 sit in the pipeline, with 6 withdrawn.
Sources, methodology & freshnessLast updated 2026-08-21 · Open ↓Close ↑
Relative strength of the investable Renaissance IPO ETF vs SPY, at the 47th percentile of the post-2013 record.
Recently priced — deals that made it out
Every deal that priced since the archive opened on August 14, 2026, newest first. The price column is the final offer price; deal size is shares × price where both disclosed. Names begin appearing in the performance tables a few sessions after they start trading.
| Date | Company | Price | Deal size |
|---|---|---|---|
| 2026-08-19 | LYNXLyntris Inc. | $17.50 | $298M |
| 2026-08-18 | XTERUKarman Line Acquisition Corp. | $10.00 | $200M |
| 2026-08-18 | NSAIUNorthStrive Acquisition Corp I. | $10.00 | $100M |
| 2026-08-13 | TBCVUThunder Bridge Capital Partners V, Ltd. | $10.00 | $261M |
| 2026-08-12 | VOGXVogenx, Inc. | $13.00 | $81M |
| 2026-08-12 | SNSCSunScout Holding Ltd | $5.00 | $16M |
| 2026-08-12 | FOILLondian Wason New Energy Tech Inc. | $22.00 | $94M |
| 2026-08-07 | TPTicketplus Ltd. | $8.00 | $15M |
| 2026-08-07 | PNAQUPinnacle Acquisition Corp | $10.00 | $200M |
| 2026-08-07 | OCLTUOceanLight Acquisition Corp | $10.00 | $100M |
| 2026-08-07 | LTGOLatigo Biotherapeutics, Inc. | $18.00 | $346M |
| 2026-08-07 | BLSMBlossomHill Therapeutics, Inc. | $16.00 | $150M |
| 2026-08-06 | BRVEBraveheart Bio, Inc. | $18.00 | $383M |
| 2026-08-05 | TCGXTCGX Acquisition Corp. | $10.00 | $75M |
| 2026-08-05 | ATTOAttovia Therapeutics, Inc. | $17.00 | $289M |
| 2026-08-04 | THEOUBOA Acquisition Corp. II | $10.00 | $125M |
| 2026-08-04 | FJDIUARC Group Securities Acquisition I | $10.00 | $105M |
| 2026-07-31 | XIIIUChurchill Capital Corp XIII | $10.00 | $360M |
| 2026-07-31 | EWAVUEast West Ave Acquisition Corp. | $10.00 | $100M |
| 2026-07-31 | APMDApnimed, Inc. | $16.00 | $192M |
Showing the 20 most recent of 35 priced deals in the archive.
The pipeline — expected and filed
Deals that have filed or set an expected date but not yet priced. Price ranges are the bankers' proposed band and routinely move — a cut range or a slipped date is the tell that the book is soft. 6 archived deals have been withdrawn — pulled deals lead a cooling calendar by weeks.
| Date | Company | Status | Price | Deal size |
|---|---|---|---|---|
| 2026-09-08 | PTTSIYATA PTT | expected | — | — |
| 2026-08-20 | FBDTFirst Breach, Inc. | expected | — | — |
| 2026-08-18 | HLNKHUALINK TECH INC | filed | — | — |
| 2026-08-18 | ADBTAdvasa Holdings, Inc. | expected | — | — |
| 2026-08-18 | —Ray Maple Inc. | filed | — | $29M |
| 2026-08-17 | BMFBANG MAI FANG HOLDINGS | filed | — | $35M |
| 2026-08-17 | ADBTAdvasa Holdings, Inc. | expected | — | — |
| 2026-08-14 | NSAIUNorthStrive Acquisition Corp I. | expected | $10.00 | $115M |
| 2026-08-14 | MOTMetaOptics Ltd | expected | $5.00–$7.00 | $24M |
| 2026-08-14 | FITFitness Fanatics Ltd | filed | — | $48M |
| 2026-08-12 | BRBMBirchBioMed Inc. | filed | — | — |
| 2026-08-11 | LEDRULeader's Advantage Acquisition Corp. | expected | $10.00 | $173M |
| 2026-08-10 | JTTTJATT III Acquisition Corp | filed | — | $69M |
| 2026-08-10 | IPHXUInflection Point Acquisition Corp. VIII | filed | — | $288M |
| 2026-08-10 | GIAUGigCapital10 Corp. | filed | — | $253M |
| 2026-08-10 | GDOZUGores Holdings XII, Inc. | filed | — | $359M |
| 2026-08-10 | ESAUEaglesky Acquisition Corp | filed | — | $115M |
| 2026-08-07 | PORTUSouthport Acquisition Corp. II | filed | — | $230M |
| 2026-08-07 | LCNSULucens Capital Acquisition Corp I | filed | — | $115M |
| 2026-08-07 | CPLMUDanneskjold & Galt Acquisition Co | filed | — | $173M |
Showing the 20 most recent of 36 pipeline entries.
Recent listings — how they've traded since
Every name in our universe that listed within the trailing 24 months, with returns from its first recorded close, the first price generally available. Returns never start from the allocated offer price. IPO-verified means the deal appears priced in our calendar archive; unverified names include SPACs, direct listings, spinoffs and uplistings. Listings enter this table after identity verification against our common-stock snapshot, so the newest debuts can lag their first trading day by a few weeks.
| Symbol | Listed | Since first close | Mkt cap | IPO |
|---|---|---|---|---|
| RNA | 2026-02-27 | -10.5% | $11.0B | — |
| AKTS | 2026-01-09 | +7.5% | $1.2B | — |
| BUDA | 2026-01-08 | +10.2% | $111M | — |
| ALUB | 2026-01-06 | +1.7% | $362M | — |
| BVC | 2025-12-24 | +23.8% | $1.6B | — |
| RENX | 2025-12-19 | -61.9% | $1M | — |
| FJET | 2025-12-18 | -54.1% | $401M | — |
| ANDG | 2025-12-17 | +113.4% | $2.6B | — |
| MDLN | 2025-12-17 | -16.4% | $38.2B | — |
| VSNT | 2025-12-15 | -15.1% | $4.5B | — |
| WLTH | 2025-12-12 | -35.0% | $1.3B | — |
| LMRI | 2025-12-11 | -32.9% | $1.4B | — |
| CDNL | 2025-12-10 | +85.1% | $1.0B | — |
| DCX | 2025-12-10 | -88.7% | $2M | — |
| XXI | 2025-12-09 | -43.2% | $2.8B | — |
| MICC | 2025-12-08 | +33.8% | $10.0B | — |
| HYNE | 2025-12-04 | +19.0% | $119M | — |
| RGNT | 2025-12-04 | -72.0% | $38M | — |
| SMJF | 2025-12-04 | +153.0% | $144M | — |
| DMII | 2025-12-03 | +2.6% | $654M | — |
| EVOX | 2025-12-03 | +2.1% | $319M | — |
| PARK | 2025-12-03 | +101.1% | $79M | — |
| PURR | 2025-12-03 | +171.3% | $432M | — |
| AIIA | 2025-11-24 | +3.2% | $193M | — |
| RNGT | 2025-11-24 | +1.4% | $312M | — |
| KRSP | 2025-11-21 | -0.9% | $481M | — |
| BCSS | 2025-11-20 | +2.0% | $594M | — |
| VACI | 2025-11-20 | +3.1% | $312M | — |
| ALIS | 2025-11-19 | +2.9% | $85M | — |
| DNMX | 2025-11-19 | +1.1% | $266M | — |
| GLOO | 2025-11-19 | -57.5% | $512M | — |
| DYOR | 2025-11-18 | +1.5% | $229M | — |
| APXT | 2025-11-17 | +1.9% | $457M | — |
| FCRS | 2025-11-17 | -0.2% | $367M | — |
| FWDI | 2025-11-17 | -39.5% | $668M | — |
| WSHP | 2025-11-14 | -84.5% | $704M | — |
| POAS | 2025-11-13 | -95.8% | $45M | — |
| CHEC | 2025-11-11 | +2.7% | $174M | — |
| LATA | 2025-11-10 | +0.4% | $230M | — |
| AERO | 2025-11-06 | -32.6% | $3.0B | — |
| BLLN | 2025-11-06 | -12.8% | $4.1B | — |
| EVMN | 2025-11-06 | -30.7% | $595M | — |
| LKSP | 2025-11-06 | +2.9% | $195M | — |
| SUNC | 2025-11-06 | +55.3% | $2.7B | — |
| ELWT | 2025-11-05 | +1.2% | $41M | — |
| XZO | 2025-11-05 | -19.7% | $1.9B | — |
| BETA | 2025-11-04 | -31.3% | $5.8B | — |
| CEPV | 2025-11-04 | +0.9% | $325M | — |
| OTGA | 2025-11-03 | +2.0% | $297M | — |
| Q | 2025-11-03 | +32.9% | $20.7B | — |
Showing 50 of 357 listings in the trailing 24 months.
The recent-listings index — and the survivorship story
An equal-weight index of every common stock listed within the trailing 24 months (365 names today), monthly rebalanced, since October 16, 2013. The history is frozen append-only: computed once, then extended one day at a time — so when a listing later dies and leaves our database, the index history it lived through never restates. The validation below is why this in-house index is the exhibit, not the gauge: the page's regimes and forward study run on the investable Renaissance IPO ETF instead.
The survivorship check — our index vs the investable Renaissance IPO ETF
Our database prunes delisted stocks with their full history, so a naively recomputed index contains only winners. The check caught exactly that: since October 16, 2013 our survivor index returned +891.1% cumulative versus +167.3% for the Renaissance IPO ETF (IPO) — 3.7× the investable fund's growth, with a daily-return correlation of 0.71. In-house equal-weight survivor index grew 3.7x the investable ETF over the same window (survivorship inflation, the RSP lesson again). The ETF is the primary series on this page; the in-house index is the beneath-the-surface exhibit.
The same check as one line: our index divided by the ETF, both rebased to 100 at the start. Flat means tracking; a persistently rising line is our survivor universe inflating past the fund that actually held the failures.
Regimes — and what happened next
The Renaissance IPO ETF's relative strength versus SPY — the investable series, not our survivor index — read as a rolling percentile of its own history and bucketed into Cold / Lagging / Neutral / Warm / Hot. Today: Neutral, at the 47th percentile. The regime split survived the edge test against baseline SPY drift. Treat it as a base rate. It is not a trade signal; the study table below carries the per-state numbers and sample sizes.
On the investable ETF basis, at least one extreme regime's forward 63-session SPY median differs from baseline by 1.5+ points with 100+ completed windows (Hot +6.31 vs +3.82 base; Cold -0.08 vs +3.82 base). Read: hot IPO appetite has been a risk-on confirmation in this 2013+ record, not a contrarian warning. Overlapping windows and one 13-year sample — tendencies, not independent samples.
| Regime | Days | Fwd 63s SPY median | Win rate |
|---|---|---|---|
| Cold | 316 | -0.1% | 49% |
| Lagging | 948 | +3.7% | 72% |
| Neutral ← today | 632 | +3.4% | 76% |
| Warm | 948 | +4.0% | 84% |
| Hot | 316 | +6.3% | 89% |
Cohorts by listing year — the boom-bust record
Every listing year's class, graded 12 months after each name's first close. These rows are survivors-only: delisted names are pruned from our database with their history, so each cohort is missing exactly the names that did worst. Read the medians as an upper bound — the academic record (Ritter) finds full IPO cohorts underperform the market for three to five years.
| Listed | Survivors | Median 12M | vs SPY |
|---|---|---|---|
| 2012 | 90 | +21.6% | +6.4% |
| 2013 | 133 | +9.8% | -9.7% |
| 2014 | 157 | -0.4% | -5.7% |
| 2015 | 147 | -7.0% | -9.6% |
| 2016 | 104 | +18.4% | +1.7% |
| 2017 | 134 | +3.8% | -8.0% |
| 2018 | 172 | -7.9% | -13.2% |
| 2019 | 155 | -11.5% | -19.7% |
| 2020 | 253 | +1.0% | -30.5% |
| 2021 | 416 | -41.6% | -40.5% |
| 2022 | 124 | -15.7% | -20.2% |
| 2023 | 119 | -22.9% | -54.8% |
| 2024 | 174 | -15.4% | -33.3% |
| 2025 | 275 | -0.7% | -25.5% |
| 2026 | 4 | — | — |
Relative strength of the investable Renaissance IPO ETF vs SPY, at the 47th percentile of the post-2013 record.
How IPO & New Listings Tracker Works
- 1Archive the calendar dailyThe upcoming and recently priced deal list is pulled from the Finnhub IPO calendar every day and archived incrementally — expected deals, priced deals with their offer price and raise size, and withdrawals. Once a deal appears it stays in the archive, so the pipeline history accumulates.
- 2Detect listings from our own price dataA stock's listing date is its first daily bar in our 5,500-symbol price database. Names that appear in the priced calendar are tagged as verified IPOs; the rest are labeled new listings, which also catches SPACs, direct listings, spinoffs and uplistings. The universe excludes ETFs, preferreds and index tickers via our common-stock filter.
- 3Build the recent-listings index — then freeze itAn equal-weight index of every common stock listed within the trailing 24 months, monthly rebalanced, computed since the Renaissance IPO ETF's 2013 inception. The history is frozen append-only: computed once, validated against the investable ETF, then extended one day at a time — so later delistings can never quietly restate the past.
- 4Grade the base rates before shipping themForward returns are graded per listing-year cohort and per relative-strength regime, and the whole study is edge-tested against the academic prior that IPO cohorts underperform for years. If our surviving names show outperformance the academic record contradicts, the page says survivorship artifact — not edge.